If the Phase 2 CRC data due end of this year/early next year comes back positive, I disagree. It could give confidence in tivantinib going forward by showing the utility in specifically screening based on MET level up-front as it would be two successive Phase 2 trials where they showed the benefit of such screening.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.